bristol myerd squibb Lehman Brothers Global Healthcare Conference

  • 472 views
Uploaded on

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
472
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
8
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. John Celentano Senior Vice President Strategy and Productivity Transformation Lehman Brothers Healthcare Conference March 19, 2008 This presentation is intended solely for an investment community/industry audience-not for promotional use community/industry audience-
  • 2. Next Generation BioPharma Best of Pharma Best of Biotech Next Generation BioPharma Selectively Innovative Continuous Integrated Portfolio Improvement Business Model Agile, Entrepreneurial and Accountable Culture This presentation is intended solely for an investment community/industry audience-not for promotional use community/industry audience- 2
  • 3. Culture On track to embed a high performance culture that supports the Next Generation BioPharma Model Agile and entrepreneurial Clear accountability and delegation of authority Innovation and performance with integrity Continuous improvement Progress to date Initiated change management program Engaging employees Created aligned incentives This presentation is intended solely for an investment community/industry audience-not for promotional use community/industry audience- 3
  • 4. Execution of BMS Biologics Strategy Adnexus Ipilimumab Devens Bulk Erbitux Manufacturing (Cancer) (Cancer) Internal Belatacept Orencia pipeline Syracuse (Solid Organ (Rheumatoid Third Party Transplant) Arthritis) Manufacturers VEGF R-2 Inhibitor (Cancer) Anti-CD137 (Cancer) This presentation is intended solely for an investment community/industry audience-not for promotional use community/industry audience- 4
  • 5. Our Productivity Approach Management Council Productivity Transformation Team Supply Chain R&D G&A Commercial Operations $400 MM $200 MM $550 MM $350 MM $1.5 Billion Cost Savings + Cost Avoidance This presentation is intended solely for an investment community/industry audience-not for promotional use community/industry audience- 5
  • 6. Top 50 Initiatives Generate Significant Proportion of Savings Savings $1.5 B Next 250 Initiatives First 50 300 Initiatives Identified Initiatives This presentation is intended solely for an investment community/industry audience-not for promotional use community/industry audience- 6
  • 7. Cost-Disciplined Science: Clinical Studies Examples: Limit over-recruitment and reduce clinical data collected Impact: Limit Over- Improved Data + Recruitment Management >$20MM Currently over- Currently collect recruit for many >25MM data points at $3/point clinical trials Proactively Collect and manage process only recruitment in a necessary data staged way through upfront cost/benefit evaluation This presentation is intended solely for an investment community/industry audience-not for promotional use community/industry audience- 7
  • 8. Apply Lean Thinking to Streamline Processes Example: Optimize Drug Supply Process Unused Supplies Reduce unused Supplies Spend supplies by ~$170MM ~$50MM >40% ~30% of supplies Improve unused at clinical enrollment sites and returned forecasts Modify inventory levels Savings >$20MM This presentation is intended solely for an investment community/industry audience-not for promotional use community/industry audience- 8
  • 9. Supply Chain Redesigned to Support BioPharma Model Strategic Filters Current 2011 27 Plants >50% Reduction Future Geographic Product Portfolio Footprint Rationalization Network segmented and specialized In-house Biologics capability Aggressive outsourcing of mature products Generating $400 Million in Productivity This presentation is intended solely for an investment community/industry audience-not for promotional use community/industry audience- 9
  • 10. Customer Model Restructured to Support BioPharma 12,000 Primary Care 10,000 Specialty 8,000 Field-Based Medical FTEs Total Field Force 6,000 4,000 2,000 0 2005 2006 2007 2008 Specialty Model synergizes Sales Force and Field-Based Medical experts Partnering on Primary Care maximizes capacity and capability while minimizing fixed overhead Increasing productivity This presentation is intended solely for an investment community/industry audience-not for promotional use community/industry audience- 10
  • 11. Growth Driven by Expanding Global Portfolio and Continued Strong Pipeline Key Products +46% +29% +21% +10% +6% New Product Launches Pipeline ipilimumab saxagliptin dapagliflozin apixaban belatacept Full Year 2007 % Increase – as reported This presentation is intended solely for an investment community/industry audience-not for promotional use community/industry audience- 11
  • 12. Plavix: 2008 Action Plan Market Leadership – Build on Brand Equity Grow Peripheral Grow Acute Arterial Disease Coronary Syndrome Maintain Business Business Stroke Business Increase Drive early Drive early diagnosis initiation in initiation in accordance accordance with Increase with guidelines penetration guidelines in diagnosed Increase hospital patients focus To Ensure Continued Improvement in Patient Care This presentation is intended solely for an investment community/industry audience-not for promotional use community/industry audience- 12
  • 13. Abilify: Drivers of Growth DTC expansion Patient focused messaging Branded & Unbranded DTC New indications Patient Focused Selling Pieces This presentation is intended solely for an investment community/industry audience-not for promotional use community/industry audience- 13
  • 14. Orencia Strategic Focus Reimbursement specialists Payer engagement Patient assistance Orencia durability / efficacy data DTC Campaign Launched This presentation is intended solely for an investment community/industry audience-not for promotional use community/industry audience- 14
  • 15. Sprycel: Drivers of Growth Enhanced profile and label in key markets – Lower 100 mg QD starting dose in chronic phase with similar efficacy and lower frequency of certain side effects – First and only TKI with randomized data regarding Gleevec in label Phase II prostate data expected at ASCO 1st Line CML registration trial initiated – Sprycel 100 mg QD vs. Gleevec 400 mg This presentation is intended solely for an investment community/industry audience-not for promotional use community/industry audience- 15
  • 16. Ixempra-Breast Cancer Business Opportunity Evolution (2008 Patients U.S. Market) # Patients Trials -087 Adjuvant 2014 + 117,000 -100 Neo-adjuvant 2012 + -115 60,000 Taxane Naïve Anthracycline / Taxane 2009 -048 38,000 Pretreated* Anthracycline / Taxane 23,000 -046 2007 Refractory* Launch -081 9,000 Anthracycline / Taxane / Capecitabine Pretreated* *Includes patients who may be contraindicated for anthracylines Source: IntrinsiQ Breast Cancer Treatment Tree Distribution of AT Pretreated vs. AT refractory patients estimated based on primary data source This presentation is intended solely for an investment community/industry audience-not for promotional use community/industry audience- 16
  • 17. Development Portfolio Life Cycle Full Development Exploratory Development Management (Registrational, Filed) • Androgen Receptor Antagonists (Cancer) • Ixempra (Ixabepilone) • Sprycel (Cancer) • IGF-1R Antagonist (Cancer) (Cancer) • VEGF R-2 Inhibitor (Cancer) • Erbitux (Cancer) • Brivanib-VEGFR/FGFR Inhibitor (Cancer) • Ipilimumab • ErbB/VEGF Receptor Inhibitor (Cancer) • Orencia (Cancer) • Anti-CD137 Antibody (Cancer) (Rheumatoid Arthritis) • Epothilone-Folate (Cancer) • Belatacept • Met Kinase Inhibitor (Cancer) • Plavix • SMO Inhibitor (Cancer) (Solid Organ Transplant) (Atherothrombosis) • Hsp90 Inhibitor (Cancer) • p38 Kinase Inhibitors (Rheumatoid Arthritis) • Saxagliptin • Avapro / Avalide • CCR2/CCR5 Dual Antagonist (Immunology) (Diabetes) (Hypertension) • CCR2 Antagonist (CV / Met) • 11βHSD Inhibitor (Diabetes) • Abilify • Dapagliflozin • DPP4 Inhibitor Backup (Diabetes) (Psychiatric Disorders) (Diabetes) • CB1 Antagonist (Obesity) • DGAT Inhibitors (CV / Met) • Baraclude • Apixaban • LXR Agonist (Atherosclerosis) (Hepatitis B) • CRF Antagonists (Affective Disorders) (Thrombosis) • Triple Reuptake Inhibitor (Depression) • Reyataz (HIV/AIDS) • Gamma Secretase Inhibitor (Alzheimer’s) • HCV Inhibitor Target 1 (Hepatitis C) • Sustiva / ATRIPLA • HCV Inhibitor Target 2 (Hepatitis C) (HIV/AIDS) • HCV Inhibitor Target 3 (Hepatitis C) • HIV Attachment Inhibitor (HIV/AIDS) • HIV Integrase Inhibitor (HIV/AIDS) As of December 2007 This presentation is intended solely for an investment community/industry audience-not for promotional use community/industry audience- 17
  • 18. BMS Late-Stage Portfolio Targets Unmet Medical Need ipilimumab dapagliflozin Clinical Advance belatacept ixabepilone apixaban saxagliptin Medical Need * Circle size is relative peak year sales by BMS estimates. This presentation is intended solely for an investment community/industry audience-not for promotional use community/industry audience- 18
  • 19. 2008 Key Data Flow Lupus: ACR, Oct 2008 Orencia Early RA: ACR, Oct 2008 RA Prevention: EULAR, June 2008 Sprycel Prostate cancer: ASCO, June 2008 Erbitux Lung cancer: ASCO, June 2008 ACTIVE-A data available: 2H 2008 Plavix CURRENT data available: 2H 2008 MBC -046 survival data: ASCO Breast, Sept 2008 Ixempra MBC -048 survival data: SABCS, Dec 2008 Ipilimumab Metastatic melanoma: ASCO, June 2008 Belatacept Ph III data available: 4Q 2008 Ph III data: ADA, June 2008 Saxagliptin Ph III data: EASD, Sept 2008 Dapagliflozin Ph IIb data: ADA, June 2008 Ph II ACS data: ESC, Aug/Sept 2008 Apixaban Ph III VTE prevention data: ASH, Dec 2008 This presentation is intended solely for an investment community/industry audience-not for promotional use community/industry audience- 19
  • 20. Next Generation BioPharma Best of Pharma Best of Biotech Next Generation BioPharma Selectively Innovative Continuous Integrated Portfolio Improvement Business Model Agile, Entrepreneurial and Accountable Culture This presentation is intended solely for an investment community/industry audience-not for promotional use community/industry audience- 20
  • 21. John Celentano Senior Vice President Strategy and Productivity Transformation Lehman Brothers Healthcare Conference March 19, 2008 This presentation is intended solely for an investment community/industry audience-not for promotional use community/industry audience-